The Royal Adelaide Hospital, colloquially known by its initials or pronounced as "the Rah", is South Australia's largest hospital, owned by the state government as part of Australia's public health care system.

There are 800 beds in Royal Adelaide Hospital.

During the past decade, Royal Adelaide Hospital conducted 321 clinical trials. In the 10-year time frame, 321 clinical trials started and 153 clinical trials were completed, i.e. on average, 47.7% percent of trials that started reached the finish line to date. In the past 5 years, 124 clinical trials started and 79 clinical trials were completed. i.e. 63.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Royal Adelaide Hospital" #1 sponsor was "Celgene" with 29 trials, followed by "Trans Tasman Radiation Oncology Group" with 17 trials sponsored, "Gilead Sciences" with 16 trials sponsored, "Kirby Institute" with 16 trials sponsored and "Abbott Medical Devices" with 16 trials sponsored. Other sponsors include 477 different institutions and companies that sponsored additional 245 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Royal Adelaide Hospital" #1 collaborator was "National Health and Medical Research Council, Australia" with 22 trials as a collaborator, "Bristol-Myers Squibb" with 9 trials as a collaborator, "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 7 trials as a collaborator, "Australasian Leukaemia and Lymphoma Group" with 6 trials as a collaborator and "Canadian Institutes of Health Research (CIHR)" with 6 trials as a collaborator. Other collaborators include 394 different institutions and companies that were collaborators in the rest 316 trials.

According to Clinical.Site data, the most researched conditions in "Royal Adelaide Hospital" are "Atrial Fibrillation" (15 trials), "Cystic Fibrosis" (15 trials), "Crohn's Disease" (14 trials), "Ulcerative Colitis" (13 trials) and "Multiple Myeloma" (12 trials). Many other conditions were trialed in "Royal Adelaide Hospital" in a lesser frequency.

Most popular intervention types in "Royal Adelaide Hospital" are "Drug" (433 trials), "Other" (57 trials), "Device" (56 trials), "Biological" (45 trials) and "Procedure" (33 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (123 trials), "Rituximab" (15 trials), "Radiotherapy" (10 trials), "Dexamethasone" (9 trials) and "placebo" (9 trials). Other intervention names were less common.

The vast majority of trials in "Royal Adelaide Hospital" are 537 trials for "All" genders, 19 trials for "Female" genders and 19 trials for "Male" genders.

Currently, there are 205 active trials in "Royal Adelaide Hospital". 3 are not yet recruiting, 120 are recruiting, 76 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 283 completed trials in Royal Adelaide Hospital, undefined suspended trials, and 59 terminated clinical trials to date.

Out of the total trials that were conducted in Royal Adelaide Hospital, 39 "Phase 1" clinical trials were conducted, 150 "Phase 2" clinical trials and 290 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 24 trials, and there were also 73 trials that are defined as “Not Applicable".

Royal Adelaide Hospital has several departments that took part in Clinical trials: "Royal Adelaide Hospital Cancer Centre" - 13 trials, "Royal Adelaide Hospital; Haematology Clinical Trials" - 10 trials, "Royal Adelaide Hospital, Department of Medical Oncology" - 4 trials, "Royal Adelaide Hospital; Hepatology" - 2 trials, "Royal Adelaide Hospital-Respiratory Clinical Trials Unit" - 2 trials, "Hyperbaric Medicine Unit, Royal Adelaide Hospital" - 2 trials, "Pain and Anaesthesia Research Clinic/Royal Adelaide Hospital" - 2 trials, "Department of Gastroenterology and Hepatology, Royal Adelaide Hospital" - 2 trials